John Liddle
Research Subjects
Research Interests
John Liddle has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Ann L. Walker
GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
3 shared publicationsDuncan S. Holmes
GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
3 shared publicationsAndrew M. Mason
2 shared publicationsAnne Bouillot
GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
2 shared publicationsAnne M. Exall
2 shared publicationsCesar Ramirez-Molina
2 shared publications
Latest Publications
- 1 October 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (20) , 126675
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors
- 1 October 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (20) , 126675
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors
- 26 April 2019
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 75 (5) , 385-391
Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. Here, the development of a surrogate crystallographic system in place of KLK5, which proved to be challenging to crystallize, is described. The biochemical robustness of the crystallographic surrogate and the suitability of the system for the study of small nonpeptidic fragments and lead-like molecules are demonstrated.
- 26 April 2019
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 75 (5) , 385-391
Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. Here, the development of a surrogate crystallographic system in place of KLK5, which proved to be challenging to crystallize, is described. The biochemical robustness of the crystallographic surrogate and the suitability of the system for the study of small nonpeptidic fragments and lead-like molecules are demonstrated.
- 1 May 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (9) , 2023-2028
The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis
- 1 May 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (9) , 2023-2028
The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis
- 1 August 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (16) , 5222-5226
4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy
- 1 August 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (16) , 5222-5226
4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy
- 12 January 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (2) , 783-796
Pyridyl-2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists: Synthesis, Pharmacokinetics, and In Vivo Potency
A six-stage stereoselective synthesis of indanyl-7-(3′-pyridyl)-(3R,6R,7R)-2,5-diketopiperazines oxytocin antagonists from indene is described. SAR studies involving mono- and disubstitution in the 3′-pyridyl ring and variation of the 3-isobutyl group gave potent compounds (pKi > 9.0) with good aqueous solubility. Evaluation of the pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2′,6′-dimethyl-3′-pyridyl R-sec-butyl morpholine amide Epelsiban (69), a highly potent oxytocin antagonist (pKi = 9.9) with >31000-fold selectivity over all three human vasopressin receptors hV1aR, hV2R, and hV1bR, with no significant P450 inhibition. Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats.
- 12 January 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (2) , 783-796
Pyridyl-2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists: Synthesis, Pharmacokinetics, and In Vivo Potency
A six-stage stereoselective synthesis of indanyl-7-(3′-pyridyl)-(3R,6R,7R)-2,5-diketopiperazines oxytocin antagonists from indene is described. SAR studies involving mono- and disubstitution in the 3′-pyridyl ring and variation of the 3-isobutyl group gave potent compounds (pKi > 9.0) with good aqueous solubility. Evaluation of the pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2′,6′-dimethyl-3′-pyridyl R-sec-butyl morpholine amide Epelsiban (69), a highly potent oxytocin antagonist (pKi = 9.9) with >31000-fold selectivity over all three human vasopressin receptors hV1aR, hV2R, and hV1bR, with no significant P450 inhibition. Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats.
- 1 October 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (20) , 6188-6194
Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor
- 1 October 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (20) , 6188-6194
Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor
- 1 May 2009
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 9 (7) , 623-639
Progress Towards the Development of Anti-Inflammatory Inhibitors of IKKβ
Abstract: The IκB kinases (IKKs) are essential components of the signaling pathway by which the NF-κB p50/RelA transcription factor is activated in response to pro-inflammatory stimuli such as lipopolysaccharide (LPS) and tumor necrosis factor (TNFα). NF-κB signaling results in the expression of numerous genes involved in innate and adaptive immune responses. The pathway is also implicated in chronic inflammatory disorders including rheumatoid arthritis (RA), chronic obstructive pulmonary disorder (COPD), and asthma. Inhibition of the kinase activity of the IKKs is therefore a promising mechanism for intervention in these diseases. Here, we will review the literature describing small molecule inhibitors of IKKβ (IKK2), the most widely studied of the IKKs.
- 1 May 2009
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 9 (7) , 623-639
Progress Towards the Development of Anti-Inflammatory Inhibitors of IKKβ
Abstract: The IκB kinases (IKKs) are essential components of the signaling pathway by which the NF-κB p50/RelA transcription factor is activated in response to pro-inflammatory stimuli such as lipopolysaccharide (LPS) and tumor necrosis factor (TNFα). NF-κB signaling results in the expression of numerous genes involved in innate and adaptive immune responses. The pathway is also implicated in chronic inflammatory disorders including rheumatoid arthritis (RA), chronic obstructive pulmonary disorder (COPD), and asthma. Inhibition of the kinase activity of the IKKs is therefore a promising mechanism for intervention in these diseases. Here, we will review the literature describing small molecule inhibitors of IKKβ (IKK2), the most widely studied of the IKKs.
- 1 January 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (1) , 90-94
The discovery of GSK221149A: A potent and selective oxytocin antagonist
- 1 January 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (1) , 90-94
The discovery of GSK221149A: A potent and selective oxytocin antagonist